HIGHLIGHTS
- who: Tobias Monschein from the Department of Neurology, Medical University of Vienna, Waehringer Guertel, u201120, Vienna, Austria have published the research: Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR), in the Journal: (JOURNAL)
- what: The aim of this paper is therefore to characterize a cohort of NTZ-treated patients from the AMSTR and to analyse follow-up data on effectiveness and safety with a follow up period of up to 14 years. The authors provide data confirming the effectiveness of NTZ in a real-world cohort of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.